Hematology Frontier

On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…

On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…

On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…

On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…

In 2025, the highly anticipated 30th European Hematology Association (EHA) Annual Congress was grandly held in Milan, Italy. This conference brought together top experts and scholars from around the world to discuss cutting-edge topics in basic research and clinical translation in the field of hematolog.Professor Daniel Hartson from the University of Cambridge delivered an insightful presentation on "Deciphering the Genomics of Aggressive Lymphoma." He systematically elaborated on the genetic complexity of Diffuse Large B-cell Lymphoma (DLBCL), shared his team's breakthrough achievements in constructing novel functional genomics models, and emphasized the critical importance of standardized molecular profiling for advancing future clinical research and personalized medicine.

On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…

The 2025 European Hematology Association (EHA) Annual Congress was grandly convened in Milan, Italy, bringing together the world's top hematology experts for an academic feast. At this congress, Professor Jesús San Miguel of the University of Navarra Clinic in Spain was honored with EHA Lifetime Achievement Award for his revolutionary contributions to the field of Multiple Myeloma (MM). In his award lecture and keynote report, titled "Curing Myeloma: A Long and Winding Road," Professor San Miguel systematically reviewed his 45-year research journey and strategically proposed five core pillars for achieving a cure for MM, charting a clear course for the future of the field.

In 2025, the 30th Annual Congress of the European Hematology Association (EHA) was held in Milan, Italy. As a premier event in the global hematology field, this year's congress attracted thousands of experts and scholars from around the world, with nearly 4,000 abstracts submitted. Among the many studies, a Phase I clinical trial of the novel trispecific antibody JNJ-79635322 (JNJ-5322) (Abstract: S100) was selected by the congress presidency as one of six "outstanding and practice-changing" pivotal studies for an oral presentation during the plenary session, owing to its breakthrough efficacy. The study showcased the astounding potential of JNJ-5322 in treating patients with Relapsed/Refractory Multiple Myeloma (RRMM).

Editor's Note: From June 12 to 15, 2025, the 30th Congress of the European Hematology Association (EHA) was held in Milan, Italy. As a premier event in the global hematology…